Liquidia's stock already trades as if the worst remedy is coming. United Therapeutics and Liquidia will tell a Delaware judge by about what they think that remedy should be.
The most important document in the Liquidia case has not been written yet.
By around , Liquidia and United Therapeutics must hand a federal judge in Delaware a proposed form of judgment spelling out what should happen to Yutrepia, Liquidia's inhaled treprostinil treatment. That filing follows a Wednesday decision that went mostly Liquidia's way on paper and almost entirely against it in the market.
The split decision
The court upheld two claims of United Therapeutics' '327 patent, numbers 1 and 14, and found that Yutrepia infringes them. Every other claim United Therapeutics asserted under the patent was ruled invalid. As both companies describe it, the two surviving claims concern patients with pulmonary hypertension tied to interstitial lung disease, or PH-ILD, rather than Yutrepia's broader pulmonary arterial hypertension use.
Investors ignored the scorecard. Liquidia fell from $70.69 to $30.26, a 57.19% loss, as roughly 16 times its usual volume changed hands. United Therapeutics gained about 12.55% to around $541.89.
Who lost more than who gained
Liquidia shed about $3.6 billion in market value in one session, while United Therapeutics added about $2.4 billion. The roughly $1.2 billion difference highlights the uneven reaction, but it is not a direct measure of profits transferred or value destroyed: the two companies have different businesses, exposures and investor expectations. Legal costs and potential disruption remain part of the uncertainty.
Two remedies, very different companies
The proposed judgment will show how far apart the parties are. United Therapeutics has said it believes the law entitles it to an order directing the Food and Drug Administration to withdraw Yutrepia's approval, which could take the drug off the U.S. market until a label without PH-ILD is cleared. It also intends to pursue damages, potentially a royalty on past sales.
Liquidia's answer is a narrower fix. It plans to ask the FDA to strip PH-ILD from Yutrepia's label and to appeal. "We respectfully disagree with the Court's decision regarding claims 1 and 14 and are fully prepared to pursue all available appellate options," Chief Executive Roger Jeffs said. The company said it cannot yet put a figure on its exposure.
The discriminating test
Those two positions describe two different businesses. Under a label carve-out, Liquidia keeps selling Yutrepia for its main indication and loses a slice of patients. Under a withdrawal order, U.S. revenue from its lead product stops for as long as relabeling takes, and damages arrive on top.
The sharp decline shows investors are concerned about restrictions on Yutrepia's future sales. The remedy filing, and the judge's response to any disagreement, could move the stock in either direction. An appeal and any request to pause the remedy while it proceeds would follow.